Metal-Complex Nucleic Acid Adjuvant Composition for Vaccine Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adjuvants used in vaccines, such as aluminum salts and TLR agonists, primarily induce humoral immune responses but are inadequate for cell-mediated immune responses, and nucleic acids like RNA and CpG motifs face stability issues due to rapid degradation in the body.
Innovation Solution
A pharmaceutical composition comprising a nucleic acid molecule stabilized by a metal complex with a specific structure, potentially including an immunogen, to enhance both humoral and cell-mediated immune responses while maintaining stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleic acid adjuvants (RNA, CpG motifs) are used to enhance immune responses, then both humoral and cell-mediated immune responses are improved, but the nucleic acid molecules are rapidly degraded in the body, reducing their stability and duration of action
Solution Approach 1:
The patent introduces a metal complex as an intermediary substance that binds to nucleic acid adjuvants (RNA, CpG motifs) and prevents their degradation by nucleases in the body. This metal complex acts as a protective mediator that stabilizes the nucleic acid molecules while allowing them to maintain their immune-stimulating function, thus resolving the contradiction between effectiveness and stability.
Solution Approach 2:
The patent creates a composite formulation combining metal complexes with nucleic acid adjuvants. This composite structure provides both the immune-stimulating properties of the nucleic acid and the stabilizing properties of the metal complex, achieving both improved reliability and enhanced stability simultaneously.
2Reliability
If conventional adjuvants (alum, oil in water emulsion) are used to induce humoral immune responses, then antibody production is improved, but cell-mediated immune responses are insufficient
Solution Approach 1:
The patent changes the chemical and molecular parameters of the adjuvant by using nucleic acid molecules (RNA, CpG motifs) instead of conventional alum or oil-based adjuvants. This parameter change enables the adjuvant to stimulate both humoral and cell-mediated immune responses, achieving versatility while maintaining effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively stabilizes nucleic acid adjuvants, enhancing both types of immune responses and providing a stable platform for vaccine development.
Implementation Method 1
a metal complex stabilizing the nucleic acid molecule and having the following structure of Formula 1
Data Source
AI summary
The present disclosure relates to a pharmaceutical composition comprising a nucleic acid molecule of an adjuvant, a metal complex stabilizing the nucleic acid molecule, and optionally an immunogen that may be a peptide or a protein, or a composition of stabilizing the nucleic acid molecule of the adjuvant comprising the metal complex. The metal complex interacts with the nucleic acid molecule of the adjuvant and/or the immunogen so as to stabilize such pharmaceutically active ingredients, and induces continuous effectiveness of the active ingredients without degradation.